임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
37건 표시
- 3상모집 중· Moderately to Severely Active Crohns DiseaseA Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
리드: 로슈
- 3상모집 중· Moderately to Severely Active Ulcerative ColitisA Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
리드: 로슈
- 3상모집 중· Neovascular Age-related Macular DegenerationA Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
리드: 로슈
- 3상모집 중· Alzheimers DiseaseA Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
리드: 로슈
- 3상모집 중· Non-Small Cell Lung CancerA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
리드: 로슈
- 3상모집 중· High Risk Cardiovascular DiseaseZilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
협력: 로슈
- 3상모집 중· Alzheimers DiseaseA Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
리드: 로슈
- 3상모집 중· Proliferative Diabetic Retinopathy (PDR)Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
협력: 로슈
- 3상모집 중· Alzheimers DiseaseScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
리드: 로슈
- 3상모집 중· Von Willebrand Disease, Type 3A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
리드: 로슈
- 3상모집 중· Moderately to Severely Active Crohns DiseaseA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
리드: 로슈
- 3상모집 중· Moderately to Severely Active Crohns DiseaseA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
리드: 로슈
- 3상모집 중· Moderately to Severely Active Ulcerative ColitisA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
리드: 로슈
- 3상모집 중· Neovascular Age-related Macular DegenerationA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
리드: 로슈
- 3상모집 중· Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
리드: 로슈
- 3상모집 중· Chronic Obstructive Pulmonary DiseaseA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
리드: 로슈
- 3상모집 중· Acute Myeloid LeukemiaVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
협력: 애브비, 로슈
- 3상모집 중· Ovarian Neoplasm EpithelialMAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
협력: 노바티스, 로슈
- 3상모집 중· Neovascular Age-Related Macular DegenerationExtension Study for the Port Delivery System With Ranibizumab (Portal)
리드: 로슈
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.